Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Alba Garcia-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad Lopez, Gonzalo Alba, Victor Sanchez-Margalet
Summary: NAFLD affects a quarter of the global population and poses a significant health and economic burden across all countries. The lack of approved pharmacotherapy and well-established diagnostic strategies for this disease highlights the urgency for further research and management efforts. Studies have shown a strong relationship between the hormone leptin and the development of NAFLD, suggesting potential advancements in disease management through further investigation of its role.
Article
Endocrinology & Metabolism
Weiwei He, Caoxin Huang, Xiulin Shi, Menghua Wu, Han Li, Qiuhong Liu, Xiaofang Zhang, Yan Zhao, Xuejun Li
Summary: This study identified transcriptomic changes in hepatic stellate cells (HSCs) in non-alcoholic steatohepatitis (NASH) patients using single-cell RNA sequencing analysis. The study also identified key functional pathways in the development of NASH. By evaluating the main pathways involved in HSC activation, this study has the potential to assess fibrosis severity in NASH.
ENDOCRINE CONNECTIONS
(2023)
Article
Biochemistry & Molecular Biology
Xiangyun Sun, Qinghong Yu, Bilian Kang, Xinyan Zhao, Hongyi Li, Helin Liu, Lin Liu, Ping Wang, Min Cong, Tianhui Liu
Summary: Activation of hepatic stellate cells (HSCs) is the main cause of liver fibrosis in non-alcoholic steatohepatitis (NASH). Diethyldithiocarbamate (DDC) inhibits the activation of HSCs in NASH through the PPARa pathway.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Hye Young Kim, Sang Bong Ahn, Jeong-Min Hong, Ju Hee Oh, Waqar Khalid Saeed, Gyu Sik Kim, Hyun Kim, Jong Koo Kang, Sukmo Kang, Dae Won Jun
Summary: BTT-105 exhibited anti-fibrotic effects in three NAFLD models, reducing lipid metabolites and increasing antioxidants in liver tissue, as well as inhibiting HSCs activation and migration. It also enhanced Nrf2 activation and decreased the PI3K-Akt pathway, ultimately ameliorating steatohepatitis and hepatic fibrosis.
Review
Pharmacology & Pharmacy
Andrea Dalbeni, Marco Castelli, Mirko Zoncape, Pietro Minuz, David Sacerdoti
Summary: Non alcoholic steatohepatitis (NASH) is an inflammatory reaction of the liver caused by excessive accumulation of lipids in hepatocytes. It can lead to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is a manifestation of metabolic syndrome, which is associated with subclinical inflammation. Platelets are involved in immune response and activation of stellate cells, and may play a key role in the development of NASH. Antiplatelet drugs have been shown to interrupt this process and improve NASH and metabolic alterations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Eveline Gart, Wim van Duyvenvoorde, Karin Toet, Martien P. M. Caspers, Lars Verschuren, Mette Juul Nielsen, Diana Julie Leeming, Everton Souto Lima, Aswin Menke, Roeland Hanemaaijer, Jaap Keijer, Kanita Salic, Robert Kleemann, Martine C. Morrison
Summary: Butyrate exerts protective effects against obesity, insulin resistance-associated NASH, and liver fibrosis. The antifibrotic effects are partly due to direct inhibition of collagen production in hepatic stellate cells by butyrate, involving deactivation of specific non-canonical TGF-beta signaling pathways.
Article
Chemistry, Multidisciplinary
Hao Shen, Han Yu, Qian-yu Li, Ya-ting Wei, Jing Fu, Hui Dong, Dan Cao, Lin-na Guo, Lei Chen, Yuan Yang, Ying Xu, Meng-chao Wu, Hong-yang Wang, Yao Chen
Summary: Non-alcoholic fatty liver disease (NAFLD) is a prevalent risk factor for hepatocellular carcinoma (HCC). The progression from NAFLD to HCC involves paracrine communication among hepatic cells. Vascular endothelial growth factor A (VEGFA) plays a crucial role in NAFLD and HCC, but its cellular communication in the transition from NAFLD to HCC is still unclear.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Medicine, Research & Experimental
Noha M. Hany, Sanaa Eissa, Manal Basyouni, Amany H. Hasanin, Yasmin M. Aboul-Ela, Nagwa M. Abo Elmagd, Iman F. Montasser, Mahmoud A. Ali, Paul J. Skipp, Marwa Matboli
Summary: This study constructed a genetic-epigenetic network linked to hepatic stellate cell (HSC) signaling and evaluated the effects of Mutaflor (R) on this network. The results showed that Mutaflor (R) administration minimized the alterations caused by NAFLD/NASH and reduced HSC activation and profibrogenic protein expression. This effect may be achieved through upregulation of RPARP AS-1 LncRNA and downregulation of miR-650, FOXA2 mRNA, and TEAD2 mRNA expression.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Qi Wang, Haoming Zhou, Qingfa Bu, Song Wei, Lei Li, Jinren Zhou, Shun Zhou, Wantong Su, Mu Liu, Zheng Liu, Mingming Wang, Ling Lu
Summary: The transcription factor XBP1 plays a critical role in the development of NASH, with its upregulation in liver tissues of NASH patients. Conditional knockout of Xbp1 in hepatocytes reduces lipid accumulation, while genetic deletion of Xbp1 in macrophages ameliorates steatohepatitis and fibrosis. Pharmacological inhibition of XBP1 shows promising therapeutic potential for NASH.
JOURNAL OF HEPATOLOGY
(2022)
Review
Medicine, General & Internal
Elizabeth E. Powell, Vincent Wai-Sun Wong, Mary Rinella
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.
Article
Biochemistry & Molecular Biology
Kozue Kanemitsu-Okada, Masanori Abe, Yoshiko Nakamura, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yohei Koizumi, Masashi Hirooka, Yoshio Tokumoto, Bunzo Matsuura, Mitsuhito Koizumi, Yoichi Hiasa
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide, and therapeutic strategies targeting multidirectional pathways are necessary. Fibrosis is closely related to prognosis, and B cell-activating factor (BAFF) is associated with NAFLD severity. This study found that BAFF plays a crucial role in the development of non-alcoholic steatohepatitis (NASH) and may be a promising therapeutic target for NASH.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Hyun-Jong Cho, Han-Jun Kim, KangJu Lee, Soufian Lasli, Aly Ung, Tyler Hoffman, Rohollah Nasiri, Praveen Bandaru, Samad Ahadian, Mehmet R. Dokmeci, Junmin Lee, Ali Khademhosseini
Summary: A liver-on-a-chip platform with bioengineered multicellular liver microtissues has been developed to replicate the pathogenesis of advanced stages of non-alcoholic fatty liver disease (NAFLD) with inflammation and fibrosis. This model includes key features such as lipid accumulation, neovascularization, inflammation, and extracellular matrix deposition, providing a deeper understanding of the mechanisms underlying fibrosis progression in NAFLD and the discovery of new drugs for different stages of NAFLD.
Article
Pharmacology & Pharmacy
Natsuko Hada, Asao Katsume, Kawasaki Kenichi, Chihiro Endo, Naoshi Horiba, Masayuki Sudoh
Summary: A new oral inhibitor CH5169356 was found to inhibit the progression of hepatic fibrosis in NAFLD and NASH by suppressing HSC activation, suggesting its potential as an oral therapeutic agent for NASH.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2023)
Review
Endocrinology & Metabolism
Takefumi Kimura, Simran Singh, Naoki Tanaka, Takeji Umemura
Summary: The prevalence of NAFLD is increasing globally, with controlling NASH events being a current medical need. Hepatic fibrosis is a key factor in NAFLD/NASH prognosis, highlighting the importance of understanding GPCRs and developing related therapies. GPCRs play a role in regulating liver function, and further research on their impact on hepatic fibrosis may lead to novel treatments for NAFLD/NASH.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
James K. Carter, Scott L. Friedman
Summary: Nonalcoholic fatty liver disease (NAFLD) is the main cause of liver disease worldwide, and nonalcoholic steatohepatitis (NASH) is a more severe form characterized by significant hepatocellular injury, inflammation, and fibrosis. Recent research has shown that heightened immune cell activity and chronic inflammation play crucial roles in the development of NASH, with hepatic stellate cells (HSCs) being the key drivers of fibrosis.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Youcai Tang, Peter Fickert, Michael Trauner, Nancy Marcus, Keith Blomenkamp, Jeffrey Teckman
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2016)
Article
Oncology
Lan Cui, Ruifeng Zheng, Wentao Liu, Peihong Shen, Youcai Tang, Junbo Luo, Wei Zhang, Guocong Jia, Yongfeng Wang, Shuaihua Zhao, Qiaoting Xie, Yanwei Li
MOLECULAR MEDICINE REPORTS
(2018)
Article
Multidisciplinary Sciences
Youcai Tang, Keith S. Blomenkamp, Peter Fickert, Michael Trauner, Jeffrey H. Teckman
Article
Cell Biology
En-yao Li, Peng-ju Zhao, Jie Jian, Bao-qi Yin, Zhen-yu Sun, Cui-xiang Xu, You-cai Tang, Hong Wu
Article
Multidisciplinary Sciences
Simeng Liu, Enyao Li, Zhenyu Sun, Dongjun Fu, Guiqin Duan, Miaomiao Jiang, Yong Yu, Lu Mei, Pingchang Yang, Youcai Tang, Pengyuan Zheng
SCIENTIFIC REPORTS
(2019)
Article
Cell Biology
Fumin Xue, Chao An, Lixiang Chen, Gang Liu, Feifei Ren, Xinhua Guo, Haibin Su, Lu Mei, Xiangdong Sun, Jinpeng Li, Youcai Tang, Xiuli An, Pengyuan Zheng
CELL COMMUNICATION AND SIGNALING
(2019)
Article
Cell Biology
En-Yao Li, Peng-Ju Zhao, Jie Jian, Bao-Qi Yin, Zhen-Yu Sun, Cui-Xiang Xu, You-Cai Tang, Hong Wu
Article
Cell Biology
Feifei Ren, Qitai Zhao, Bin Liu, Xiangdong Sun, Youcai Tang, Huang Huang, Lu Mei, Yong Yu, Hui Mo, Haibin Dong, Pengyuan Zheng, Yang Mi
JOURNAL OF CELLULAR PHYSIOLOGY
(2020)
Article
Health Care Sciences & Services
Chuan Liu, Wancong Wang, Jiahui Yang, Pan Song, Fuhao Li, Bin Liu, Jinpeng Li, Huimei Xu, Yang Mi, Youcai Tang, Pengyuan Zheng
ANNALS OF PALLIATIVE MEDICINE
(2020)
Article
Oncology
Kai Zhang, Lei Zhang, Yang Mi, YouCai Tang, FeiFei Ren, Bin Liu, Yi Zhang, PengYuan Zheng
Letter
Gastroenterology & Hepatology
Chuan Liu, Jiahui Yang, Wancong Wang, Pengyuan Zheng, Youcai Tang
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Environmental Sciences
Xinying Wang, Ming Gao, Zihan Wang, Weiqi Cui, Jingxian Zhang, Weijie Zhang, Yu Xia, Bo Wei, Youcai Tang, Xia Xu
Summary: This study revealed that oridonin exerts a protective effect on BPA-induced liver injury by restoring oxidative stress and XOD activity, reducing organ damage. Metabolomics analysis identified alterations in purine metabolism, amino acid biosynthesis, and phenylalanine metabolism as potential underlying mechanisms.
SCIENCE OF THE TOTAL ENVIRONMENT
(2021)
Article
Pathology
Yuying Ma, Xuecui Yin, Zhenzhen Qin, Xiaofei Ke, Yang Mi, Pengyuan Zheng, Youcai Tang
Summary: The study shows that Plin5 deficiency can alleviate NAFLD by regulating lipid metabolism and inhibiting lipogenesis, providing a new strategy for the treatment of NAFLD.
JOURNAL OF COMPARATIVE PATHOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Yang Mi, Haibin Dong, Xiangdong Sun, Feifei Ren, Youcai Tang, Pengyuan Zheng
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
(2020)
Letter
Medicine, General & Internal
Chuan Liu, Jiahui Yang, Wancong Wang, Yang Mi, Youcai Tang, Pengyuan Zheng
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
(2020)